Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K. Morimoto K, et al. Among authors: tokuda s. Cancer Lett. 2024 Apr 10;587:216692. doi: 10.1016/j.canlet.2024.216692. Epub 2024 Feb 9. Cancer Lett. 2024. PMID: 38342232 Free article.
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
Tanimura K, Yamada T, Horinaka M, Katayama Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Yoneda K, Yano S, Sakai T, Takayama K. Tanimura K, et al. Among authors: tokuda s. Cancer Lett. 2021 Dec 1;522:119-128. doi: 10.1016/j.canlet.2021.09.018. Epub 2021 Sep 15. Cancer Lett. 2021. PMID: 34534615
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K. Ishida M, et al. Among authors: tokuda s. Thorac Cancer. 2022 Jan;13(2):173-181. doi: 10.1111/1759-7714.14236. Epub 2021 Nov 17. Thorac Cancer. 2022. PMID: 34791812 Free PMC article.
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Nakamura R, et al. Among authors: tokuda s. J Cancer Res Clin Oncol. 2022 Nov;148(11):2985-2994. doi: 10.1007/s00432-021-03866-2. Epub 2021 Nov 26. J Cancer Res Clin Oncol. 2022. PMID: 34825950
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Katayama Y, et al. Among authors: tokuda s. Cancer Med. 2022 Feb;11(4):944-955. doi: 10.1002/cam4.4504. Epub 2022 Jan 14. Cancer Med. 2022. PMID: 35029047 Free PMC article.
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, Hibino M, Tani N, Takeda T, Yamaguchi H, Tachibana Y, Takumi C, Hiraoka N, Takeshita M, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Yamada T, Takayama K. Tanaka S, et al. Among authors: tokuda s. Diagnostics (Basel). 2022 Feb 6;12(2):423. doi: 10.3390/diagnostics12020423. Diagnostics (Basel). 2022. PMID: 35204513 Free PMC article.
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Hiranuma O, Yamada T, Kanda H, Nakano T, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: tokuda s. JTO Clin Res Rep. 2022 Jun 8;3(7):100353. doi: 10.1016/j.jtocrr.2022.100353. eCollection 2022 Jul. JTO Clin Res Rep. 2022. PMID: 35789793 Free PMC article.
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC.
Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: tokuda s. JTO Clin Res Rep. 2022 Aug 6;3(9):100388. doi: 10.1016/j.jtocrr.2022.100388. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082280 Free PMC article.
273 results